Eravacycline Impurity NEW

Eravacycline Impurity

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com

• Product Information

• Product Number: E062017

• English Name: Eravacycline Impurity 17

• English Alias: (4aS,8aS,9S)-3-(benzyloxy)-4a-((tert-butyldimethylsilyl)oxy)-9-(dimethylamino)-8a,9-dihydronaphtho[2,3-d]isoxazole-4,5(4aH,6H)-dione

• CAS Number: None

• Molecular Formula: C26H34N2O5Si

• Molecular Weight: 482.64

• Advantages: As a reference standard for Eravacycline Impurity 17, it has a well-defined chemical structure, and its purity has been strictly determined and verified. It has good stability and uniformity. In drug quality control, it can serve as a reliable reference substance, ensuring the accuracy and repeatability of impurity detection results for Eravacycline-related products, and providing strong support for quality assessment in the drug research and production process.

• Applications: It is mainly used in the quality research and control of Eravacycline bulk drugs and formulations. It can be used to develop and validate impurity detection methods such as high-performance liquid chromatography (HPLC) and liquid chromatography - mass spectrometry (LC - MS). In the stability study of Eravacycline, it is used to monitor the changes of this impurity under different conditions. It also helps to evaluate the impact of the production process on impurity generation, thereby optimizing the process and ensuring that drug quality meets relevant standards.

• Background Description: Eravacycline is a new type of tetracycline antibacterial drug, which has important applications in the field of anti-infective treatment. In the process of its research and development and production, the control of impurities is directly related to the safety and effectiveness of drugs. As one of the potential impurities of Eravacycline, the study of Eravacycline Impurity 17 helps to comprehensively understand the impurity profile of Eravacycline, improve quality standards, meet drug regulatory requirements, and ensure the safety of patients' medication.

• Research Status: Currently, the research on Eravacycline Impurity 17 mainly focuses on the establishment and optimization of impurity analysis methods. Detection techniques are improved to enhance the sensitivity and accuracy of detecting this impurity. At the same time, researchers are also exploring its generation mechanism during the synthesis of Eravacycline, attempting to reduce its production by improving the process. In addition, the research on the stability of this impurity during drug storage and its impact on the efficacy and safety of Eravacycline is also gradually underway, in order to provide a more comprehensive scientific basis for the quality control of Eravacycline.

• 
  

NOTE！

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com

NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!